We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
26
Alkermes
ALKS
$8.08B
$44.7M 0.25%
1,500,000
– –
CCXI
27
DELISTED
ChemoCentryx, Inc.
CCXI
$44.4M 0.25%
1,792,657
+875,795
+96% +$19.3M
KDNY
28
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$44.3M 0.25%
2,534,102
+200,000
+9% +$3.14M
INSM icon
29
Insmed
INSM
$22.6B
$42.5M 0.24%
2,156,001
– –
IMTX icon
30
Immatics
IMTX
$1.2B
$38.5M 0.22%
4,423,731
– –
DBVT
31
DBV Technologies
DBVT
$799M
$37.3M 0.21%
1,461,426
– –
JBIO
32
Jade Biosciences
JBIO
$1.16B
$32.4M 0.18%
59,143
– –
AMRN
33
Amarin Corp
AMRN
$300M
$31.5M 0.18%
1,058,490
– –
VSTM icon
34
Verastem
VSTM
$522M
$31.3M 0.18%
2,249,075
– –
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$2.49B
$28.1M 0.16%
470,974
+26,530
+6% +$1.63M
TSVT
36
DELISTED
2seventy bio
TSVT
$27.2M 0.15%
2,062,744
– –
KNSA icon
37
Kiniksa Pharmaceuticals
KNSA
$6.12B
$27.1M 0.15%
2,799,577
– –
BMEA icon
38
Biomea Fusion
BMEA
$88.9M
$25.2M 0.14%
2,104,559
+553,114
+36% +$3.24M
ALT icon
39
Altimmune
ALT
$578M
$24.3M 0.14%
2,075,403
+1,003,365
+94% +$6.19M
NVTA
40
DELISTED
Invitae Corporation
NVTA
$24.1M 0.14%
9,873,488
– –
PACB icon
41
Pacific Biosciences
PACB
$432M
$24.1M 0.14%
5,444,963
– –
XENE icon
42
Xenon Pharmaceuticals
XENE
$6.16B
$22.9M 0.13%
751,639
– –
HRTX icon
43
Heron Therapeutics
HRTX
$92.5M
$22.7M 0.13%
8,131,678
– –
MRUS
44
DELISTED
Merus
MRUS
$22.5M 0.13%
995,397
-1,042,072
-51% -$21.8M
VERV
45
DELISTED
Verve Therapeutics
VERV
$21.6M 0.12%
1,416,530
– –
DSGN icon
46
Design Therapeutics
DSGN
$743M
$20.1M 0.11%
1,436,636
– –
AFMD
47
DELISTED
Affimed
AFMD
$18.3M 0.1%
659,683
+144,366
+28% +$4.94M
TIL icon
48
Instil Bio
TIL
$49.2M
$18M 0.1%
194,685
– –
OTIC
49
DELISTED
Otonomy, Inc.
OTIC
$17.5M 0.1%
8,412,634
+567,942
+7% +$1.18M
DNLI icon
50
Denali Therapeutics
DNLI
$3.77B
$17.3M 0.1%
588,738
+500,000
+563% +$13.1M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Baker Bros. Advisors held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Baker Bros. Advisors added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Baker Bros. Advisors's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Baker Bros. Advisors fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q2 2022.
  • Baker Bros. Advisors's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.